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Abstract: Background: Cholinesterase inhibitors and glutamate blockers are commonly used for the treatment of
cognitive impairment in Alzheimer’s disease. The aim
was to evaluate the effects of rivastigmine and memantine alone or in combination in rats with scopolamine-impaired memory.
Method: 5 groups of rats were used: control, scopolamine
(model), model with rivastigmine, model with memantine,
and model with both drugs. Active avoidance test was performed and the number of conditioned responses, unconditioned responses and intertrial crossing were recorded.
Passive avoidance tests step-through with criteria latency
of reaction 180 s in the light chamber and step-down with
criteria latency of reaction 60 s on the platform were done.
Results: Control rats learned the task and kept it on
memory tests. Scopolamine treated rats failed to perform
it. The rivastigmine, memantine and its combination
groups showed increased CRs during learning and
memory retention tests. In both passive avoidance tests
an increased latency of reaction was observed in the drug
treated groups.
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Conclusion: The combination of both drugs rivastigmine
and memantine is more effective than the use of the single
drug in cognitive impaired rats. Cholinesterase inhibitors
and NMDA blockers may be combined in the treatment of
different kind of dementias.
Keywords: rivastigmine, memantine, drug combination,
scopolamine model, rats.

1 Introduction
Of the five drugs that have been approved for symptomatic
treatment of Alzheimer’s disease (AD), (tacrine, donepezil, rivastigmine, galantamine and memantine), most act
via the inhibition of acetylcholinesterase (AChE) or butyrilcholinesterase (BuChE).
Rivastigmine, a carbamate derivative of physostigmine, is unique in blocking AChE. It induces the attachment of a carbamyl residue instead of performing the usual
microsomal activity. Rivastigmine is therefore classified as
a pseudo-irreversible inhibitor of AChE and BuChE [1].
The changes in acethylcholine (ACh) levels positively
modulate glutamatergic function in animal models [2].
Memantine is a non-competitive NMDA glutamate receptor channel inhibitor that binds to the disocilpine site [3].
NMDA receptors play a unique and vital role in subcellular
signaling. Calcium influx through NMDA receptors initiates signaling cascades important for both synaptic plasticity and cell survival; however, over-activation of these
receptors leads to toxicity and cell death. More specifically,
it has been found, that NMDA receptors located at the
synapse stimulate cell survival pathways, while extra-synaptic receptors signal for cell death [4]. This interplay
between synaptic and extra-synaptic NMDA receptors
has been studied exclusively in cortical and hippocampal neurons [5]. A deficit in NMDA receptor-dependent
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neocortical plasticity has been found in patients with
AD and transgenic rodents [6]. Synaptic scaling is a form
of synaptic plasticity, that involves NMDA receptors and
tends to restore neuronal activity to baseline levels was
described by Watt et al, [7] and Turrigiano et al, [8]. Diffuse
synaptic loss in AD should cause a compensatory increase
(scaling) in the excitability of adjacent healthy neurons by
increasing presynaptic glutamate release [9] and postsynaptic receptor density [10]. Memantine’s inhibitory ability
has been shown to significantly improve behavioral symptoms of AD, and is currently used for treatment of moderate to severe AD [5].
The hypothesis that a combination of cholinergic and
glutamanergic intervention could potentially provide a
more effective therapy for AD. It has been suggested that
the specific combination of an AChE inhibitor and the
NMDA receptor inhibitor memantine might yield a synergistic effect [11].
The aim of this study was to evaluate and compare
the effects of rivastigmine or memantine alone or in combination of the two, on rats with scopolamine-impaired
memory.

2 Experimental procedures
All experiments were carried out according to the
guidelines for the use of laboratory animals in EU and
Bulgaria. Permission for the study was obtained by the
Bulgarian Food Safety Agency No73/03.12.2012 and the
Ethics Committee of the Medical University Plovdiv
No3/05.07.2013.

2.1 Chemicals
Memantine hydrochloride (Sigma)
Rivastigmine tartrate (Aldrich)
(-) Scopolamine hydrochloride (Sigma)

2.2 Animals
This study used 40 male Wistar rats with body weights of
180-220g, divided into 5 groups (n=8). The animals were
kept under standard laboratory conditions in an 08.00 –
20.00 h light/dark cycle and were provided with food and
water ad libitum. Groups were divided according to the
administered treatments, as follows: 1) saline 0.1 ml/100g
b.w. i.p. + saline 0.1 ml/100g b.w. p.o.; 2) scopolamine 1mg/
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kg i.p. + saline 0.1 ml/100g b.w. p.o.; 3) scopolamine 1mg/
kg i.p. + rivastigmine 2 mg/kg p.o.; 4) scopolamine 1mg/kg
i.p. + memantine 10 mg/kg p.o. and 5) scopolamine 1mg/
kg i.p. + rivastigmine 2 mg/kg p.o. + memantine 10/mg/
kg p.o. Substances were administered once daily for the
duration of the experiment, 60 minutes before testing.
We used the effective doses of rivastigmine and
memantine, improving effects on learning and memory
processes in our preliminary experiments on naïve rats.
Scopolamine was used as a model of impaired learning
and memory in a dose, effective in our experiments studying other cholinesterase inhibitors.

2.3 Behavioral tests
2.3.1 Active avoidance testing:
An automatic reflex conditioner for an active avoidance
“shuttle box” (Ugo Basile, Italy) was used. The rats were
placed into one of the chambers. Learning sessions were
performed daily over 5 consecutive days. Each session
consisted of 30 trials with the following parameters: 6s
light and buzzer (670 Hz and 70 dB), 3s 0.4 mA foot shock,
12s pause. A memory retention session was performed
7 days after the last learning session (12th day) with the
same parameters, but with the absence of a foot shock.
The following parameters were recorded automatically: 1
– number of conditioned responses (CR; avoidances); 2 –
number of unconditioned responses (UCR; escapes from
foot shock); 3 - number of intertrial crossings.

2.3.2 Passive avoidance testing (two passive avoidance
tests were used):
An automatic set-up for a passive avoidance “stepthrough” test (Ugo Basile, Italy) was used in a wire cage
with 2 separate light and dark compartments. The rat was
placed into the light chamber. The test parameters were as
follows: door closed for 6s, door opened to allow entry into
darkened chamber for 12s, 9 sec later 0.4mA foot shock
and door closed. Learning sessions were performed over
2 consecutive days, a short memory retention session was
performed 24 hours later (3rd day), and a long memory
retention session was performed on the 10th day. Memory
retention tests were performed using the same parameters, except for the absence of a foot shock. Sessions consisted of 3 trials separated by 30 minute intervals. The
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learning criterion used was a latency of reaction of 180 ± 2
seconds staying in the light chamber.
An automatic set-up for a passive avoidance “stepdown” test (Ugo Basile, Italy) was used in a wire-floor
single cage with a round central plastic platform. The rat
was placed gently on the plastic platform. Learning sessions consisted of 2 trials separated by a 60 minute interval. During each trial, electrical stimulation (0.4mA) was
delivered to the wire floor for a duration of 10 s when the
animal step down from the platform. Learning sessions
were performed over 2 consecutive days, a short memory
retention session was performed 24 hours later (3rd day),
and a long memory retention session was performed on
the 7th day. Memory retention tests were performed using
the same parameters, but with the absence of a foot shock.
A latency of reaction of 60 s (the rat was required to remain
with all 4 paws on the platform for more than 60 s) was
used as a criterion for learning and retention.

2.4 Statistical analysis
All observed parameters were expressed as means ±
S.E.M. for each group. The comparison between groups
was made using the repetitive measures ANOVA followed

by a Tukey post-hoc test for multiple comparison on the
Excel and Instat computer programs. A P-value of P<0.05
was considered representative of a significant difference.

3 Results
3.1 Effects on active avoidance test
The control group of rats (saline) showed an increased
number of conditioned responses (avoidances) on the 3rd,
4th, and 5th days of learning sessions and on the memory
retention session of the 12th day (P<0.05), when compared
to 1st day. The animals treated with scopolamine (model
group) showed decreased number of avoidances (P<0.05)
on the 3rd, 4th and 5th days’ learning sessions and during
memory retention testing, compared to respective day
control. Animals with model treated with rivastigmine
showed increased number of avoidances on learning
session (1st to 5th days) and on memory test (P<0.05) compared to the respective day scopolamine group. Rats with
model treated with memantine also showed increased
number of avoidances on learning session and on memory

Figure 1A: Effects of rivastigmine, memantine and combinatory treatment on active avoidance testing in rats with scopolamine-impaired
memory.
Abscissa – days of testing; Ordinate – number of conditioned responses (CR; avoidances). OP<0.05 compared to respective day control group
data; *P<0.05 compared to respective day scopolamine group data; #P<0.05 compared to Day 1 control group data.
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retention test ({<0.05) compared to the respective day of
model group. Rats with model, treated with rivastigmine
and memantine also showed increased number of avoidances on learning session and on memory test (P<0.05),
compared with the respective day model group, but
express only the tendency to increased it compared to
rivastigmine or memantine alone groups (Figure 1A).
The saline group of rats did not show significant
changes in the number of UCRs (escapes) during any of
the five learning sessions or during retention testing compared to first day performance. Animals treated with scopolamine (model group) made relatively fewer escapes
during all learning sessions and during retention testing,
compared to respective day control group. Animals with
scopolamine model, treated with rivastigmine showed a
greater number of escapes on the 1st, 2nd and 5th days of
learning sessions and on the retention test (P<0.05) compared to respective day model group. Rats with model,
treated with memantine showed an increased number of
escapes only on the 2nd day of learning sessions (P<0.05)
when compared to the scopolamine group. Rats with
model treated with rivastigmine and memantine in combination showed a greater number of escapes on the 1st
day of learning sessions and on the memory retention test
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(P<0.05) when compared to respective day scopolamine
group performance (Figure 1B).
Neither the control nor the scopolamine (model)
groups showed significant changes in the number of
intertrial crossings during either the learning or memory
retention test sessions, compared to 1st day of respective
group. Rats with model, treated with rivastigmine showed
an increased number of intertrial crossings on the 1st, 3rd,
4th and 5th days of learning session (P<0.05) and on the
memory retention test (P<0.01), compared to respective
day of model group. Rats with model, treated memantine
showed an increased number of intertrial crossings on the
4th and 5th days of learning session (P<0.05), compared to
respective day model group. Animals with model, treated
with rivastigmine and memantine in combination made a
greater number of intertrial crossings on the 1st (P<0.01),
4th and 5th days (P<0.05) of learning session, compared to
the respective day of model group (Figure 1C).

3.2 Effects on step-through passive
avoidance tests
The control group of rats showed a prolonged latency
of reaction (P<0.05) during both short- and long-term

Figure 1B: Effects of rivastigmine, memantine and combinatory treatment on active avoidance testing in rats with scopolamine-impaired
memory.
Abscissa – days of testing; Ordinate – number of unconditioned responses (UCR; escapes). *P<0.05 compared to respective day scopolamine group data;
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Figure 1C: Effects of rivastigmine, memantine and combinatory treatment on active avoidance testing in rats with scopolamine-impaired
memory.
Abscissa – days of testing; Ordinate – number of intertrial crossings. *P<0.05 and **P<0.01 compared to respective day scopolamine group
data;

memory tests, compared to 1st day learning session.
Animals in the scopolamine group (model group) showed
a shortened latency of reaction (P<0.05) on the 1st and 2nd
learning sessions, compared to respective day of controls.
Rats with model, treated with rivastigmine do not change
the latency of reaction on learning and memory retention,
compared to the respective day of model group. Rats with
model, treated with memantine, and rats with model,
treated with the combination of the two (rivastigmine
and memantine) showed a prolonged latency of reaction
during the 1st and 2nd days of learning sessions (P<0.05),
compared to respective day of model group (Figure 2).

3.3 Effects on step-down passive avoidance
testing
The control group of rats showed a prolonged latency of
reaction (P<0.05) on the 2nd day of learning and on both
short- and long-term memory retention tests, compared to
1st day. Animals with scopolamine (model group) demonstrated a shortened latency of reaction on two days learning, short- and long-term memory retention tests (P<0.05),
compared to those days controls. Animals with model
treated with rivastigmine showed a prolonged latency

of reaction on the 1st and 2nd days of learning sessions
and during short- and long-term memory retention test
(P<0.05), compared to the same days model group. Rats
with model treated with memantine showed prolonged
latency of reaction (P<0.05) on learning and short and
long memory retention tests, compared to the respective
days of model group. Rats with model treated with the
combination showed prolonged latency (P<0.05) on learning and on short and long memory tests, compared to the
respective days of model group (Figure 3).

4 Discussion
Our experiments suggest that control rats learned the task
and keep it during memory tests in both active and passive
avoidance tests. Rats with scopolamine-induced memory
impairment failed to perform during learning and memory
retention sessions of active avoidance test and during
step-through and step-down passive avoidance tests.
Rivastigmine improved learning in active avoidance
testing and performance during memory retention test of
rats with scopolamine-impaired memory, as evidenced by
the increases in observed CR and UCR values (Figure1A,
Brought to you by | College of William and Mary
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Figure 2: Effects of rivastigmine, memantine and combinatory treatment on step-through passive avoidance testing in rats with scopolamine-impaired memory.
Abscissa – days of testing; Ordinate – latency of reaction in seconds. OP<0.05 compared to respective day control group data; *P<0.05 compared to the respective day scopolamine group data; #P<0.05 compared to the Day 1 control group data.

Figure 3: Effects of rivastigmine, memantine and combinatory treatment on step-down passive avoidance testing in rats with scopolamineimpaired memory.
Abscissa – days of testing; Ordinate – latency of reaction in seconds. OP<0.05 compared to the respective day control group data; *P<0.05
compared to the respective day scopolamine group data; #P<0.05 compared to the Day 1 control group data.
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B and C). Rivastigmine also resulted in enhanced performance of rats with model of impaired memory in the stepdown passive avoidance test, but do not change it in stepthrough test (Figure 2 and Figure 3).
Generally, rivastigmine enhances cholinergic function by prolonging the activity of endogenously released
acetylcholine [1, 12]. There is evidence that an abundance
of ACh will positively modulate glutamatergic function in
animal models [2]. In acting on muscarinic receptors, ACh
enhances the NMDA-mediated component of excitatory
postsynaptic potentials [13]. Multiple lines of evidence
suggest, that ACh might influence the excitability of cortical and hippocampal glutamatergic networks [14] and
plays a prominent role on neocortical excitability through
complex interactions with glutamatergic pathways.
In the present study, administration of memantine on
rats with model of amnesia, improved performance during
learning and memory retention sessions in active avoidance testing, as evidenced by the increase in CR values
in the data (Figure 1A, B and C). Memantine administration also improved the latency of reaction during learning
(step-through) and memory (both step-through and stepdown) sessions (Figure 2 and Figure 3).
It is well known that amyloid-beta peptides (Aβ)
observed in AD can trigger apoptotic cascades in neurons.
Miguel-Hidalgo JJ et al, [15] found that memantine, an
uncompetitive antagonist of NMDA receptors approved for
the treatment of moderate to severe Alzheimer’s disease,
can prevent neurodegeneration induced by intracranial
Aβ (1-40) injection. The study hypothesized that memantine would prevent Aβ (1-40) induced cognitive impairment, neurodegeneration and apoptosis in hippocampal neurons of rats and improve performance in active
avoidance testing. Based on their results, the authors concluded, that memantine can prevent amyloid-triggered
expression of apoptosis-related markers and concomitant
cognitive deficits. Others [16] found, that memantine prevents memory consolidation failure induced by soluble
beta amyloid in rats.
Our results showed that the administration of rivastigmine and memantine in combination on rats with model
of impaired memory, improved learning and the formation
of memory in rats during active avoidance tests. The combination treatment also improved performance during the
learning sessions of step-through testing and during both
learning and memory retention sessions of step-down
passive avoidance testing.
Jung JY et al, [17] studied the effects of cholinesterase inhibitors donepezil and galanthamine in combination with the NMDA receptor blocker memantine on
sleep-wake architecture in rats. The study found that

the combination of donepezil and memantine induced
a significant increase in total wake duration as well as a
decrease in total slow-wave sleep, REM sleep, and delta
activity. Additionally, it was found that memantine administration alone increased sleep latency and motor activity.
Based on these results, it was concluded that cholinesterase inhibitors might be useful as anti-dementia drugs that
do not cause sleep disturbances. Others [18] establish that
acetylcholinesterase inhibitors galantamine and donepezil, used in small doses fully reversed both methyllycaconitine- and scopolamine- induced cognitive dysfunction
in mice.
Alzheimer’s disease is characterized by imbalances
of various neurotransmitter systems long before the onset
of symptoms. It has been proposed that a treatment plan
which enhances both cholinergic and glutamatergic
systems, implemented at the earliest stages of the disease,
would be advantageous in counteracting the decline of
cortical synaptic plasticity [19]. Our results are in favour of
such hypothesis. The mechanism underlying the synergistic interaction between the two drugs is unclear. There are
multiple neural substrates that might be involved in this
interaction. One notable is the hippocampal excitatory
circuit. This circuit receives tonic excitatory cholinergic
input from the medial septum and the diagonal band of
Broca. Glutamate, on the other hand, acts on NMDA receptors located on inhibitory GABAergic interneurons within
the septum to inhibit the activity of cholinergic neurons
that project to the hippocampus [12]. Consistent with this
localization, behaviour and elecrophysiological studies
have shown that memantine increases cholinergic signalling and excitability in the mouse hippocampus and that
this action is blocked by the muscarinic antagonist scopolamine [20]. Therefore, the memory potentiation observed
and documented in our study may be due to a cholinergic activation resulting from concomitant treatment with
memantine and rivastigmine, acting through N and M
cholinergic pathways in accordance with the hypothesis
of Busquet et al [21].
Further investigation of the neurochemical alterations
involved in these key cognitive areas of the brain may lead
to complex implications about the mechanisms of learning and memory. One such implication is that the combination of a cholinesterase inhibitor with a glutamate
antagonist may be a beneficial option for the treatment
of AD [22]. Perhaps the use of small doses of rivastigmine
and memantine in a multitargeted approach to treatment
could overcome some of the major limitations of current
drug therapies and provide such benefits as increased efficacy and a reduced incidence of adverse drug reactions.
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